Back to results
US 11,633,442 B2Granted
Methods for combining adoptive T cell therapy with oncolytic virus adjunct therapy
AssigneeTvax Biomedical I, LLC
InventorsGary Wood, Jochen Harald Stritzker
Life of this patent
Estimating the term…
Abstract
The present invention relates to augmenting the effects of adoptive T cell therapy, such as TVAX Immunotherapy, using adjunct treatment with an oncolytic virus, such as a vaccinia virus, to treat various types of cancer or other proliferative disorders. Immunomodulatory compounds can be used to further augment to effects of the therapy.
Claims19
A cancer immunotherapy method for treating cancer in a patient comprising:
- vaccinating the patient with a vaccine comprised of the patient's own malignancy and an immunologic adjuvant;
- isolating primed T lymphocytes from lymphoid tissue, peripheral blood or cancer tissue of the patient;
- stimulating the primed T lymphocytes to differentiate into effector T lymphocytes in vitro;
- stimulating the effector T lymphocytes to proliferate in vitro;
- administering an oncolytic virus to the patient after said step of vaccinating the patient with a vaccine comprised of the patient's own malignancy;
- and
- infusing the effector T lymphocytes back into the patient after said administering of the oncolytic virus step.
4 more elements
Dependencies are inferred from the claim text.